Form 4 for DFTX Definium Therapeutics, Inc.
Accepted 2026-09-04 21:30:03 ET · period of report 2026-09-02 · accession 0001193125-26-384042 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | 2026-09-04 21:30 | 2026-09-02 | DFTX | Barrow Robert | CEO, Dir | A - Grant | $0.00 | +40.0K | 1.51M | +3% | $0 |
| T | 2026-09-04 21:30 | 2026-09-03 | DFTX | Barrow Robert | CEO, Dir | S - Sale | $37.94 | -19.0K | 1.49M | -1% | -$721.7K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Shares | 2026-09-02 | A | A | 40,000 | $0.00 | 1,513,663 | D | — | — | (F1) The common shares represent the first tranche of performance share units granted effective February 3, 2026. Each performance share unit represented a contingent right to receive one common share based on, and subject to, the achievement of certain clinical and regulatory milestones set forth in the Performance Share Unit Award Agreement. (F2) Amount includes 417 shares acquired under the Definium Therapeutics, Inc. 2024 Employee Share Purchase Plan on August 17, 2026. |
| 2 | Common | Common Shares | 2026-09-03 | S | D | 19,023 | $37.94 | 1,494,640 | D | — | — | (F3) Represents the number of Common Shares sold to satisfy withholding tax obligations in connection with the settlement of vested performance restricted stock units, pursuant to sell-to-cover elections under a Rule 10b5-1 plan adopted on June 15, 2022 (F4) The reported price is a weighted average sales price. These shares were sold in multiple transactions on September 3, 2026 at prices ranging from $37.46 to $38.94. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |